Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Is Codexis Stock a Buy?

TheMotleyFool

0 0

By digging through SEC filings of institutional shareholders, investors can unearth promising stocks hidden to most. Codexis (NASDAQ: CDXS) fits this bill. With a business focused on developing enzymes, Codexis has built a growing revenue stream through partnerships and licenses to its platform technology.

As of Sept. 30, institutional investors held over 86% of the outstanding shares. These include big names like BlackRock, Vanguard, and Fidelity as well as healthcare specialist funds including Vivo Ventures and Opaleye Management.

Source Fool.com

Like: 0

CDXS

Teilen